Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBIT: 2016-2025

Historic EBIT for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $4.4 million.

  • Akebia Therapeutics' EBIT rose 135.58% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 151.00%. This contributed to the annual value of -$50.5 million for FY2024, which is 9.11% down from last year.
  • Akebia Therapeutics' EBIT amounted to $4.4 million in Q3 2025, which was down 68.42% from $14.1 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year EBIT high stood at $34.1 million for Q2 2022, and its period low was -$79.3 million during Q2 2021.
  • Its 3-year average for EBIT is -$5.9 million, with a median of -$9.0 million in 2023.
  • As far as peak fluctuations go, Akebia Therapeutics' EBIT plummeted by 1,141.27% in 2024, and later skyrocketed by 261.48% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' EBIT stood at -$65.3 million in 2021, then soared by 92.55% to -$4.9 million in 2022, then skyrocketed by 128.22% to $1.4 million in 2023, then plummeted by 1,141.27% to -$14.3 million in 2024, then soared by 135.58% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $14.1 million for Q2 2025, and $13.5 million during Q1 2025.